Download Files:
Ribociclib
$72 – $216
Products Details
Product Description
– Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].
Web ID
– HY-15777
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C23H30N8O
Citations
– Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):4001-4011.|Biomed Chromatogr. 2020 Mar;34(3):e4783.|Biomed Pharmacother. 2019 Feb 18;112:108602. |Biomed Res Int. 2020 Jun 11;2020:9525207.|Breast Cancer Res. 2019 Dec 26;21(1):150.|Cancer Discov. 2023 Dec 4.|Cancer Res. 2019 Oct 15;79(20):5245-5259.|Cancers (Basel). 2022, 14(22), 5481|Cancers. 2020 Jun 16;12(6):1596.|Cell Chem Biol. 2019 Aug 15;26(8):1067-1080.e8. |Cell Death Dis. 2020 Sep 15;11(9):754.|Cell Rep Med. 2023 Sep 12;101200.|Cell Rep. 2017 Oct 31;21(5):1386-1398.|Cell Rep. 2020 Aug 4;32(5):107995.|Cell. 2023 Jun 8;186(12):2628-2643.e21.|Clin Cancer Res. 2015 Nov 1;21(21):4947-59.|Department of Biochemistry. 2020 Oct.|Eur J Cancer. 2018 Oct;102:10-22.|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.|Front Oncol. 2022 Apr 8;12:819003.|Fundam Clin Pharmacol. 2021 Feb 1.|Harvard Medical School LINCS LIBRARY|Int J Biol Sci. 2019 Jan 1;15(3):522-532. |J Chromatogr B. 2020 Jun 15;1147:122142.|J Infect Dis. 2018 Nov 22;218(suppl_5):S365-S387.|J Pharmaceut Biomed. 2021, 113933.|J Transl Med. 2022 May 13;20(1):217.|J Virol. 2023 May 23;e0037023.|Leuk Res. September 2022, 106920.|Mil Med Res. 2022 Dec 19;9(1):71.|Mol Cancer Ther. 2018 May;17(5):897-907.|Mol Cell. 2017 Oct 19;68(2):336-349.e6.|Mol Oncol. 2017 Aug;11(8):1035-1049.|Nat Commun. 2021 Sep 10;12(1):5386.|Nat Commun. 2022 Aug 10;13(1):4689.|Nat Commun. 2019 Jun 28;10(1):2860.|Nature Cancer. 2021 Apr;2(4):429-443.|Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 4.|NPJ Precis Oncol. 2021 Mar 19;5(1):20.|Patent. US20220354911A1.|PLoS One. 2022 Dec 22;17(12):e0279522.|Research Square Print. November 7th, 2022|RSC Adv. 2020, 10(38):22668-22683.|Sci Adv. 2022 Dec 23;8(51):eadc8911.|Sci Rep. 2021 Mar 8;11(1):5374.|Sci Rep. 2022 Jul 20;12(1):12420.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|bioRxiv. 2023 Sep 16.|Clin Cancer Res. 2015 Nov 1;21(21):4947-59.|JCI Insight. 2021 Dec 21;e154402.|Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.|Nat Commun. 2021 Aug 25;12(1):5112.
References
– [1]Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.|[2]VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21(13):2905-10.
CAS Number
– 1211441-98-3
Molecular Weight
– 434.54
Compound Purity
– 99.98
SMILES
– O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 6.25 mg/mL (ultrasonic)
Target
– CDK
Isoform
– CDK4;CDK6
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
